Navigation Links
pHase Pharmaceuticals Announces New Venture
Date:4/22/2010

DALLAS, April 22 /PRNewswire/ -- pHase Pharmaceuticals, LLC announces the launch of its new drug development company.  pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.  

Having developed numerous commercially successful new drugs, the pHase team has now identified an unmet clinical need in a large and growing market.  The principals of pHase have already invested significant capital to initiate the development of a superior form of delivery for a drug in the allergy/immunology space that offers significant clinical, cost and ease of use advantages over the current form of treatment.  In addition, the team has identified and confirmed a streamlined regulatory path that accelerates time to market while decreasing development costs.  

The team consists of Dr. Lynn Yohana Howard, Dr. Nicholas Farina, Edward Walters and Chris Howard.  Members of this team were instrumental in the development of such blockbuster drugs as Aricept, Aciphex, Altocor/Altoprev, Fortamet and Sodium Valproate.  The teams extensive experience in both the formulation of new compounds along with the management of the manufacturing process, clinical trials and FDA approvals, particularly 505 b(2), positions them to succeed in this new venture.

pHase is currently in the process of securing additional capital to fund the 2nd phase of their initial drug development project.  Further information on the team can be found on the company's website www.phasepharma.com.

Carillon Capital Partners is serving as an advisor to pHase and is leading the current effort to raise growth capital for the company.  Carillon Capital Partners is a boutique investment bank, strategic advisor and merchant bank specializing in helping a broad range of companies in the financial services, healthcare, technology and defense industries.  For further information, please see www.carilloncapital.com.


'/>"/>
SOURCE Carillon Capital Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/19/2017)... Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will ... at the Sheraton Hotel in Toronto, Ontario . ... Company is scheduled to present on Tuesday, May 2 at 10:00 ... of the Board, Tony Holler will also attend the ... For more details about ...
Breaking Medicine Technology:
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, ... of Cisco Select certification and SMB specialization. Altura is now qualified to ... In earning the Select Certification, Altura fulfilled the training and exam requirements for ...
(Date:4/22/2017)... White Plains, NY (PRWEB) , ... April 22, ... ... Quarterly Report, which shows that U.S. consumers can save an average of 70% ... Even greater savings (up to 97%) are available when purchasing from other countries. ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their ... have been used to remove decayed dental matter, and that teeth were then filled ...
(Date:4/21/2017)... ... 21, 2017 , ... Contrary to popular perception, a new ... at noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a ... the United States. The study, Trends in Fighting and Violence Among Adolescents ...
(Date:4/21/2017)... ... ... Brady (NYSE:BRC), a global leader in industrial and safety printing ... vinyl label materials received certification for the BS5609 British Marine Standard. This internationally recognized ... for use on chemical drums shipped by sea. , ÔÇťAchieving BS5609 certification ...
Breaking Medicine News(10 mins):